ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FDBK Feedback Plc

17.75
-0.50 (-2.74%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB00BJN59X09 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -2.74% 17.75 17.00 18.50 18.25 17.75 18.25 90,680 08:49:32
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electronic Computers 1.03M -2.92M -0.0666 -2.67 8M
Feedback Plc is listed in the Electronic Computers sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 18.25p. Over the last year, Feedback shares have traded in a share price range of 17.75p to 150.00p.

Feedback currently has 43,814,779 shares in issue. The market capitalisation of Feedback is £8 million. Feedback has a price to earnings ratio (PE ratio) of -2.67.

Feedback Share Discussion Threads

Showing 14526 to 14548 of 15050 messages
Chat Pages: Latest  590  589  588  587  586  585  584  583  582  581  580  579  Older
DateSubjectAuthorDiscuss
05/12/2023
20:47
I reckon it was a buy as my dummy sells were showing 70p. Maybe Tom is betting the house on it haha
digger2779
05/12/2023
17:37
Late trade.

Looks like a £72k buy to me.

17:10:51 72.00 100,000 Unknown* 70.00 74.00 72.00k O

Getting close to 7th December - betting on the outcome?

lr2
28/11/2023
17:52
...and Bleepa is still partnered with them.



A little surprised that we didn't get a corresponding late trade following that big 'un this morning.

lr2
28/11/2023
14:17
Yep big trade (buy I think) but not budged the sp
digger2779
28/11/2023
11:37
Yump, he’d like to get his hands on Texrad but can’t afford it so he’s hoping Fdbk go down the pan so he can get it cheaply.
ducatiman
28/11/2023
09:21
That’s a big trade
ducatiman
27/11/2023
12:08
yump sentimental attachment, if you have normal human feelings it will not be difficult to understand. Why are you still here though. ?
ydderf
27/11/2023
11:19
Why are you still here ?
yump
27/11/2023
10:57
Sentiment has changed for 'businesses' with no earnings and barely any sales. The fundamentals are assets which is IP and some burning net cash. A rational valuation would be projected net cash in say six months time and something for potential income which is realistically discounted to npv. According to my thinking that's about 30-35p. Happy to debate it rationally with someone seriously interested in agreeing what a fair arms length valuation might be. Anyone?
ydderf
24/11/2023
13:57
Palantir is not a day to day practical patient management tool. Bleepa is.
yump
23/11/2023
15:10
Looking at the 5 year chart we are pretty close to touching cloth so to speak. Can't quite make out the early 2020 bottom but it's not a pretty sight.
digger2779
23/11/2023
15:06
I did think the that the Palantir contract might be bad news for Feedback. If a hospital is 'given' the Palantir records handler, they will be less likely to get the funds to licence Bleeper: it will be argued that Bleeper is unnecessary given the Palantir product.

Anyone remember the Lorenzo fiasco? A health records system for the NHS being developed by Fujitsu, finally cancelled with losses of more than £10 billion in 2011.
hxxps://www.panorama-consulting.com/nhs-it-system-failure/#:~:text=Yet%2C%20nine%20years%20later%2C%20the,more%20than%20%C2%A310%20billion.

I suspect, as with the Post Office Horizon system, and hospital trying to say that the Palantir package is not fit for purpose will be ignored.

gnnmartin
23/11/2023
14:33
Is that now an all time low?
Nice one TO. Still getting a big bonus? Still earning more than Rishi? Still can’t afford any shares?
Consolidation working out well?
Go now please and take a few other parasites with you

ducatiman
22/11/2023
15:42
Our local surgery relocated to a nice newish overly large building, where the waiting room is generally 80% empty, because of phone “consultations”.

When you phone them the voice says “all our agents are busy”. “Agents” WTF ?

So amongst all the amazing tech developments and personalisations, the practice bought or subscribed to a sad generic phone system.

How bad a reflection on the attitude to us as customers is that and pretty dire reflection of either basic competence or the limitations of forced? choices available.

I have no confidence in the purchasing competence of any part of the NHS and I reckon it will be random luck if Bleepa gets chosen at QVH.

yump
21/11/2023
18:26
It almost certainly won't work sufficiently well to achieve many of the stated aims. The government will declare it a success and the medical staff will work around large swathes of it. Money down a drain. Bleepa will be unlikely to be bothered by it.
lr2
21/11/2023
18:09
Further to that article, LR2, the NY Times article included this interesting sentence:-

On Tuesday, the N.H.S. said additional funds were set aside to build privacy features and for other companies to bid for building new products onto the platform in the future.

ged5
20/11/2023
23:30
Re my post #11077, it appears that despite the misgivings of many doctors Palantir has been given £480 million of taxpayers' money to implement their Federated Data Platform (FDP).



Our government is truly a soft touch.

lr2
20/11/2023
17:00
And nobody wanted to buy it Internal budgets are for the birds. Rightly Tom shelved it
privateryan
20/11/2023
10:56
Texrad was the future, a future Feedback shareholders will never know now. The strategic decision to focus upon Bleepa has cost millions which could have been spent developing and marketing Texrad. To be fair, shareholders implicitly supported this move, which has turned out to be disastrous so far. Texrad had sales and internal projections in 2016-7 were for sales to be in the millions a few years down the line, i.e. a year or two ago.......
ydderf
18/11/2023
15:51
Texrad is a superb product. The reason I first invested here.
A shame it is no longer being marketed and developed.
I’m sure one day it will be resurrected by someone.
It must have a value. If Fdbk don’t want it then sell it on.
I think I know someone who would like it!

ducatiman
17/11/2023
23:33
Another appearance of Texrad, this time in a thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health.

Investigating the potential of real-world data to improve outcomes for patients with lung cancer.

lr2
16/11/2023
11:33
You don't think there could possibly be some who have a longer time frame than the three weeks up to the QVH deadline? Surely not!
ged5
16/11/2023
11:27
And I thought we had a little leak last night. Wrong about that. Roll on the new financial year.
lr2
Chat Pages: Latest  590  589  588  587  586  585  584  583  582  581  580  579  Older